Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-74
SponsorNHS Greater Glasgow and Clyde
About this trial
The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease.
Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms.
The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism.
Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.
Eligibility criteria
Qualifiers
Adults ≥18 years < 75years
Diagnosis of PsO or PsA, made by a dermatologist or rheumatologist.
Selected to start secukinumab/ bimekizumab/ Ixekizumab as part of their standard clinical care by their usual dermatology team for PsO or rheumatology clinical team for PsA in line with the license for secukinumab/ bimekizumab/ Ixekizumab and NICE/SMC criteria.
No contraindications to MRI (for example metal fragments or implantable devices not compatible with MRI. (no extra x-ray images will be obtained to check placement of metal fragments or clips insitu. Existing images may be used to check for possible contraindications)
Disqualifiers
Inability to provide written informed consent
Severe physical impairment (e.g., blindness, deafness, paraplegia).
Clinically important, active infections e.g. active TB
History of inflammatory bowel disease
Trial design
Treatments tested in this trial
- Secukinumab
- Bimekizumab
- Ixekizumab
- Placebo
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
NHS Greater Glasgow and Clyde
Lead sponsor
University of Glasgow
Collaborator
Medical Research Council
Collaborator
Source ClinicalTrials.gov